Source-grounded facts extracted from BIO-TECHNE Corp's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BIO-TECHNE Corp reported financial results for quarter and nine months ended March 31, 2026.
“A copy of the press release issued by Bio-Techne Corporation on May 6, 2026, describing the results of operations for the quarter and nine months ended March 31, 2026, and its financial condition as of March 31, 2026 is attached hereto as Exhibit 99.1.”
Amy Herr was appointed as Independent Director at BIO-TECHNE Corp.
“On January 30, 2025, Bio-Techne Corporation (the “Company”) appointed Dr. Amy Herr to the Company’s Board of Directors as an independent director.”
BIO-TECHNE Corp reported the third quarter ending March 31, 2024 results: revenue $303.4 million, EPS $0.31.
“reported its financial results for the third quarter ending March 31, 2024. Third Quarter FY2024 Highlights ● Third quarter organic revenue increased by 2% (3% reported) to $303.4 million. ● GAAP earnings per share (EPS) was $0.31 versus $0.43 one year ago. Delivered adjusted EPS of $0.48 compared to $0.53 one year ago. ● Strong commercial execution in”
Dr. Judith Klimovsky was appointed as Director at BIO-TECHNE Corp.
“On April 24, 2024, Bio-Techne Corporation (the “Company”) temporarily expanded the size of the Board of Directors from ten to eleven members and appointed Dr. Judith Klimovsky to the company's Board of Directors as an independent director.”
BIO-TECHNE Corp reported financial results for second quarter ended December 31, 2023.
“A copy of the press release issued by Bio-Techne Corporation on February 1, 2024, describing the results of operations for the quarter ended December 31, 2023, and its financial condition as of December 31, 2023 is attached hereto as Exhibit 99.1.”
Dr. Matthew McManus was appointed as President – Diagnostics and Genomics Segment at BIO-TECHNE Corp.
“On January 5, 2024, Bio-Techne Corporation (the “Company”) announced the appointment of Dr. Matthew McManus, age 55, as President – Diagnostics and Genomics Segment (“President DGS”) effective January 8, 2024.”
BIO-TECHNE Corp reported first quarter ended September 30, 2023 results: revenue $276.9 million, EPS $0.31.
“its financial results for the first quarter ended September 30, 2023. First Quarter FY2024 Highlights ● First quarter organic revenue increased by 2% (3% reported) to $276.9 million. ● GAAP earnings per share 1) (EPS) was $0.31 versus $0.55 one year ago. Delivered adjusted EPS 1) of $0.41 compared to $0.45 one year ago. ● Our ExoDx prostate test and GMP”
BIO-TECHNE Corp shareholders approved Ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm at the 2024-06-30 meeting.
“Proposal No. 5 – The shareholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2024. 40 For Against Abstain 140,734,676 5,247,721 35,466”
BIO-TECHNE Corp shareholders approved Frequency of future advisory votes on executive compensation to occur every year.
“Proposal No. 4 – The shareholders approved the frequency of future advisory votes on executive compensation to occur every year. 39 1 Year 2 Years 3 Years Abstain 139,718,743 141,528 939,375 1,150,172”
BIO-TECHNE Corp shareholders rejected Non-binding resolution approving the compensation of the Company’s named executive officers.
“Proposal No. 3 – The shareholders voted against a non-binding resolution approving the compensation of the Company’s named executive officers, as described in the Proxy Statement: 9, For Against Abstain Broker Non-Vote 49,894,295 91,277,734 777,789 4,068,045”
BIO-TECHNE Corp shareholders approved Election of directors.
“Proposal No. 2 – The shareholders elected each of the nominees to the Board of Directors: For Against Abstain Broker Non-Vote Robert V. Baumgartner 100,149,013 41,734,415 66,390 4,068,045 Julie L. Bushman 132,251,087 9,638,369 60,362 4,068,045 John L. Higgins 116,991,416 24,891,094 67,308 4,068,045 Joseph D. Keegan 134,547,666 7,343,701 58,451 4,068,045 Charles R. Kummeth 139,037,662 2,847,756 64,400 4,068,045 Roeland Nusse 136,502,096 5,384,164 63,558 4,068,045 Alpna Seth 134,785,952 7,102,985 60,881 4,068,045 Randolph C. Steer 116,461,357 25,398,613 89,848 4,068,045 Rupert Vessey 134,555,098 7,335,534 59,186 4,068,045 Each nominee was elected by a majority voting standard defined in the Amended and Restated Articles of Incorporation.”
BIO-TECHNE Corp shareholders approved Set the number of directors at nine.
“Proposal No. 1 – The shareholders voted to set the number of directors at nine: For Against Abstain 141,242,833 672,919 34,066”
Chuck Kummeth retired as Director at BIO-TECHNE Corp.
“Mr. Kummeth will also retire from the Board of Directors on such date.”
Kim Kelderman was appointed as Director at BIO-TECHNE Corp.
“Also effective February 1, 2024, Mr. Kelderman will be appointed Chief Executive Officer and Director.”
Kim Kelderman was appointed as Chief Executive Officer at BIO-TECHNE Corp.
“Also effective February 1, 2024, Mr. Kelderman will be appointed Chief Executive Officer and Director.”
Kim Kelderman was appointed as Chief Operating Officer at BIO-TECHNE Corp.
“Effective November 1, 2023, Kim Kelderman will be appointed as Chief Operating Officer of the Company.”
Chuck Kummeth was appointed as Senior Advisor at BIO-TECHNE Corp.
“Effective February 1, 2024, Mr. Kummeth will transition from Chief Executive Officer to Senior Advisor until the date of his retirement on July 1, 2024.”
Chuck Kummeth retired as Chief Executive Officer at BIO-TECHNE Corp.
“Effective February 1, 2024, Mr. Kummeth will transition from Chief Executive Officer to Senior Advisor until the date of his retirement on July 1, 2024.”
BIO-TECHNE Corp reported financial results for the quarter ended March 31, 2023.
“A copy of the press release issued by Bio-Techne Corporation on May 3, 2023, describing the results of operations for the quarter ended March 31, 2023”
BIO-TECHNE Corp reported financial results for the quarter ended December 31, 2022.
“A copy of the press release issued by Bio-Techne Corporation on February 2, 2023, describing the results of operations for the quarter ended December 31, 2022, and its financial condition as of December 31, 2022 is attached hereto as Exhibit 99.1.”
Brenda Furlow retired as general_counsel at BIO-TECHNE Corp.
“Mr. Bohnen succeeds Brenda Furlow, who has announced her intention to retire on March 3, 2023.”
Shane Bohnen was appointed as Senior Vice President, General Counsel and Corporate Secretary at BIO-TECHNE Corp.
“appointed Mr. Shane Bohnen, age 48, as an executive officer of the Company in the position of Senior Vice President, General Counsel and Corporate Secretary, effective March 3, 2023.”
BIO-TECHNE Corp: Increased authorized shares of common stock from 100,000,000 to 400,000,000 (effective 2022-10-27).
“At the 2022 annual meeting of shareholders of the Company held on October 27, 2022 (the “Annual Meeting”), the shareholders approved an amendment and restatement of the Company’s articles of incorporation to increase the number of authorized shares of the Company’s common stock from 100,000,000 to 400,000,000.”
BIO-TECHNE Corp shareholders approved The shareholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2023 at the 2022-10-27 meeting.
“Proposal No. 5 – The shareholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2023. For Against Abstain 34,862,262 856,480 5,701”
BIO-TECHNE Corp shareholders approved The shareholders ratified an amendment to increase the number of shares of authorized common stock at the 2022-10-27 meeting.
“Proposal No. 4 – The shareholders ratified an amendment to increase the number of shares of authorized common stock. For Against Abstain 35,648,572 68,310 7,561”
BIO-TECHNE Corp shareholders approved The shareholders adopted a non-binding resolution approving the compensation of the Company’s named executive officers, as described in the Proxy Statement at the 2022-10-27 meeting.
“Proposal No. 3 – The shareholders adopted a non-binding resolution approving the compensation of the Company’s named executive officers, as described in the Proxy Statement: For Against Abstain Broker Non-Vote 21,321,031 13,045,755 286,774 1,070,883”
BIO-TECHNE Corp shareholders approved The shareholders elected each of the nominees to the Board of Directors at the 2022-10-27 meeting.
“Proposal No. 2 – The shareholders elected each of the nominees to the Board of Directors: For Against Abstain Broker Non-Vote Charles R. Kummeth 34,092,428 546,544 14,588 1,070,883 Robert V. Baumgartner 24,822,872 9,195,158 635,530 1,070,883 Randolph C. Steer 31,246,852 3,392,776 13,932 1,070,883 John L. Higgins 27,963,915 6,675,747 13,898 1,070,883 Roeland Nusse 33,805,594 834,332 13,634 1,070,883 Julie L. Bushman 34,398,791 242,354 12,415 1,070,883 Joseph D. Keegan 32,918,324 1,721,906 13,330 1,070,883 Alpna Seth 33,163,651 1,475,674 14,235 1,070,883 Rupert Vessey 32,917,182 1,721,925 14,453 1,070,883 Each nominee was elected by a majority voting standard defined in the Amended and Restated Articles of Incorporation.”
BIO-TECHNE Corp shareholders approved The shareholders voted to set the number of directors at nine at the 2022-10-27 meeting.
“Proposal No. 1 – The shareholders voted to set the number of directors at nine: For Against Abstain 35,575,971 139,956 8,516”
Chuck Kummeth departed as Chief Executive Officer at BIO-TECHNE Corp.
“On August 4, 2022, Bio-Techne Corporation (the “Company”) announced Chuck Kummeth’s plan to retire from his position as Chief Executive Officer effective June 30, 2024”
N. David Eansor departed as President, Protein Sciences Segment at BIO-TECHNE Corp.
“Mr. Geist succeeds N. David Eansor, who has announced his intention to retire.”
William Alexander Geist was appointed as President, Protein Sciences Segment at BIO-TECHNE Corp.
“On December 17, 2021, the Compensation Committee of the Board of Directors of Bio-Techne Corporation (the “Company”) appointed Mr. William Alexander Geist, age 52, as an executive officer of the Company in the position of President, Protein Sciences Segment, effective January 3, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.